Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 840.99M P/E 15.63 EPS this Y -927.30% Ern Qtrly Grth -
Income -24.14M Forward P/E -4.95 EPS next Y 20.40% 50D Avg Chg 33.00%
Sales 295.66M PEG - EPS past 5Y - 200D Avg Chg 12.00%
Dividend N/A Price/Book 247.50 EPS next 5Y - 52W High Chg -56.00%
Recommedations 1.50 Quick Ratio 1.97 Shares Outstanding 257.15M 52W Low Chg 138.00%
Insider Own 10.10% ROA 6.84% Shares Float 213.86M Beta 1.13
Inst Own 56.16% ROE - Shares Shorted/Prior 20.69M/26M Price 2.97
Gross Margin 38.42% Profit Margin -8.09% Avg. Volume 5,070,545 Target Price 9.67
Oper. Margin 12.59% Earnings Date May 10 Volume 6,403,431 Change 11.24%
Agenus Inc. News
08/10/22 News Flash: Analysts Just Made A Substantial Upgrade To Their Agenus Inc. (NASDAQ:AGEN) Forecasts
08/09/22 Agenus (AGEN) Q2 2022 Earnings Call Transcript
08/09/22 Agenus (AGEN) Reports Q2 Loss, Tops Revenue Estimates
08/09/22 Agenus Provides Corporate Update and Second Quarter 2022 Financial Report
08/02/22 Agenus to Participate at BTIG Biotechnology Conference
08/01/22 What Is The Ownership Structure Like For Agenus Inc. (NASDAQ:AGEN)?
08/01/22 Agenus Announces First Patient Dosed in Phase 1 Study of AGEN1571 (anti-ILT2) in Advanced Solid Tumors
07/27/22 Agenus to Provide Corporate Update and Second Quarter 2022 Financial Report
07/26/22 Why Shares of Agenus Inc. Rose 10.1% on Tuesday
07/10/22 3 Amazing Stocks Under $10
07/05/22 Houston real estate giant Transwestern bets big on Vacaville's biotech industry
07/02/22 Agenus (NASDAQ:AGEN) shareholders have endured a 64% loss from investing in the stock a year ago
06/30/22 Agenus to Participate at William Blair’s Biotech Focus Conference
06/29/22 Why Agenus Stock Is Soaring Today
06/29/22 Agenus Touts 'Unprecedented Activity' For Botensilimab/Balstilimab Combo In Colorectal Cancer
06/29/22 Agenus Shows Unprecedented Activity for Botensilimab/Balstilimab Combination in Microsatellite Stable Colorectal Cancer at ESMO World GI Congress
06/21/22 Agenus to Host Investor Webcast to Review Late-Breaking Botensilimab and Balstilimab Data Presented at ESMO World GI Congress
06/10/22 GSK’s RSV vaccine candidate for older adults, containing Agenus’ QS-21 STIMULON™ as part of GSK’s AS01 adjuvant, reports positive pivotal data supporting initiation of global regulatory submissions
06/02/22 Does Agenus (NASDAQ:AGEN) Have A Healthy Balance Sheet?

Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops vaccine programs comprising Prophage vaccine candidate; and QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an anti-CTLA-4 monospecific antibody that is in Phase 1/2 clinical trial; AGEN2373, an anti-CD137 monospecific antibody that is in Phase 1 clinical trial; AGEN1423, a tumor microenvironment conditioning anti-CD73/TGFß TRAP bi-functional antibody that has completed Phase 1 clinical trial; AGEN1777, an anti-TIGIT bispecific antibodies; and AGEN1327, a human monoclonal antibody. In addition, the company develops INCAGN1876, an anti-GITR monospecific antibody; INCAGN1949, an anti-OX40 monospecific antibody; INCAGN2390, an anti-TIM-3 monospecific antibody; INCAGN2385, an anti-LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4; AGENT 797, an iNKT cells that is in Phase 1 clinical trial for solid tumors, multiple myeloma, and viral ARDS, as well as in clinical stage to treat hematological malignancies and multiple myeloma/B cells; and AGEN1884, a first-generation anti-CTLA-4 monospecific antibody. Agenus Inc. operates under ASV, Agenus, AutoSynVax, EVAMPLIX, MiNK, PSV, PhosPhoSynVax, Prophage, Retrocyte Display, and Stimulon trademarks. It has collaborations with Incyte Corporation, Merck Sharpe & Dohme, Recepta Biopharma SA, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.

AGEN Chatroom

User Image medianTrader Posted - 1 hour ago

$EVGN $PAVM $AGEN $BGRY jumpin’ jumpin’ 🔥 🔥🔥🔥

User Image oliveinvest Posted - 3 hours ago

Sacrifice a wee bit of upside for downside protection ☁. Like this variable return strategy for $AGEN Make up to 39.6% (113.2% annualized) AGEN can fall 15% before you start to lose. Sell 1 $3.5 put Exp 1/20/23 Capital Req. $250.66 👉🏼Click my profile link to see how its done.

User Image Moon37 Posted - 23 hours ago

$AGEN The divine intervention is coming. Trust that you are in the right place

User Image OracleofOntario Posted - 23 hours ago

$AGEN It seems to require Devine intervention to get this stock to hold above $3.

User Image Brad12445 Posted - 1 day ago

$NSAV check out $AGEN for something to make back losses

User Image Apollo1452 Posted - 1 day ago

$AGEN AGEN is the rare stock that is good for day and/or swing trades or a long term hold imo.

User Image Apollo1452 Posted - 1 day ago

$AGEN AGEN is partnered with 7 major big pharma companies..... https://investor.agenusbio.com/static-files/e9101e50-36c6-420c-baa1-cba20134fded

User Image Apollo1452 Posted - 1 day ago

$AGEN Strong earnings CC. Cash on hand $238M, $25M milestone payment due for QS-21 STIMULON, revenue $21M up +$10M over LY. "Regarding our partnered antibodies in active development, in addition to the earlier mentioned MERC-licensed antibody, MK-4830, the list includes our anti-TIGIT bispecific AGEN1777 licensed to Bristol-Myers along with our four immunotherapies licensed to Incyte. These are all advancing in the clinic and as these programs successfully progress, they have the potential to trigger milestone payments to Agenus totaling close to $3 billion in addition to sales-based royalties for those molecules that reach commercial launch." https://seekingalpha.com/article/4531960-agenus-inc-agen-ceo-garo-armen-on-q2-2022-results-earnings-call-transcript

User Image chrisdacs Posted - 1 day ago

$AGEN how many of you shorts still wear masks? Just asking for a friend .

User Image EarningsInsider Posted - 1 day ago

William Blair Raises Agenus Q3 2022 Earnings Estimates to ($0.20) EPS (Previously ($0.21)). https://www.marketbeat.com/x/1271724 $AGEN

User Image EarningsInsider Posted - 1 day ago

B. Riley Raises Agenus Q3 2022 Earnings Estimates to ($0.13) EPS (Previously ($0.21)). https://www.marketbeat.com/x/1271723 $AGEN

User Image Biotechguy21 Posted - 1 day ago

$AGEN How about that Dilution today? 🥃

User Image ChartMill Posted - 1 day ago

Squeeze play pattern detected by our stock screener for $AGEN, $ORMP and $HTHT. https://www.chartmill.com/stock/stock-screener?sid=12&f=sqds,v1_50b300,sl_ti_105_X,exch_us&v=3&timeframe=DAILY&type=CANDLES&months=0.05&width=400&cl=F&o1=0&o2=57&op1=14&op2=20,1.5,10&utm_source=stocktwits&utm_medium=screener&utm_content=Stock_Screener:_Momentum_Squeeze_Play_Setups&utm_campaign=social_tracking

User Image risenhoover Posted - 1 day ago

$AGEN / Agenus files S-8 registration statement (stock option plan) https://fintel.io/sf/us/agen?utm_source=stocktwits.com&utm_medium=Referral&utm_campaign=filing

User Image stockilluminati Posted - 1 day ago

$AGEN https://www.stockilluminati.com/agen/filings.php - Agenus Inc. - Common Stock files form S-8 today, check out the details.

User Image Quantisnow Posted - 1 day ago

$AGEN 📜 SEC Form S-8 filed by Agenus Inc. https://quantisnow.com/i/3274299?utm_source=stocktwits 45 seconds delayed.

User Image GDS_investing Posted - 2 days ago

$AGEN looking great for inverse head and shoulders pattern target price for the pattern 4.70$ area 7.5$ stock imo or BUYOUT LONG and STRONG $AGEN

User Image BYGBURRITO Posted - 2 days ago

$AGEN inverse head and shoulders on the yearly chart?

User Image Moon37 Posted - 2 days ago

$AGEN The moon has returned! Soon a great deal will give AGEN the wings its needs to fly! Rejoice!

User Image PRGuiney Posted - 3 days ago

$AGEN Does anyone know when dilution is happening? Want to get in but do so on a dip…

User Image Luckmaker Posted - 3 days ago

$HLBZ f+ck you shorts $TEAM $AGEN $KODK

User Image MilaGoldframe01 Posted - 3 days ago

$AGEN just found time to listen to the call. cash balance 238m, significant revenue increase. i like it. nfa

User Image AmberMakesMoney Posted - 3 days ago

$AGEN Earnings Agenus beat estimated earnings by 26.09%, reporting an EPS of $-0.17 versus an estimate of $-0.23. Revenue was up $10.20 million from the same period last year.

User Image AmberMakesMoney Posted - 3 days ago

$AGEN Agenus Q2 EPS $0.17 Up From $(0.37) YoY, Sales $20.93M Beat $18.70M Estimate

User Image STCKPRO Posted - 4 days ago

$AGEN NEW ARTICLE : B.Riley Financial Remains a Buy on Agenus (AGEN) https://www.stck.pro/news/AGEN/32646096

User Image Biotechguy21 Posted - 4 days ago

$AGEN that’s not the problem. Dilution and more dilution. 👇🏼👇🏼👇🏼👇🏼👇🏼👇🏼

User Image chrisdacs Posted - 4 days ago

$AGEN damn good earnings call. Now if the world can get their stupid chip manufacturing figured out we can all start making money. Damn good call.

User Image tickeron Posted - 4 days ago

$AGEN reports Earnings today. A good addition to the trading plan for the week! $AGEN in -10.47% Downtrend, declining for three consecutive days on August 1, 2022. View odds for this and other indicators: https://srnk.us/go/3905002

User Image Robert121212 Posted - 4 days ago

$AGEN why is this down ?

User Image stockilluminati Posted - 4 days ago

$AGEN https://www.stockilluminati.com/agen/news.php - Agenus Inc. (AGEN) CEO Garo Armen on Q2 2022 Results - Earnings Call Transcript

Analyst Ratings
HC Wainwright & Co. Buy Mar 2, 22
HC Wainwright & Co. Buy Dec 16, 21
B. Riley FBR Buy Apr 22, 19
H.C. Wainwright Neutral Oct 28, 16
Jefferies Buy Jul 29, 16
Maxim Group Buy Mar 11, 16
JMP Securities Market Outperform Mar 9, 16
Maxim Group Hold Oct 27, 15
Oppenheimer Outperform Jun 10, 15
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
O'Day Steven J Chief Medical Office.. Chief Medical Officer Jan 04 Sell 3.06 38,679 118,358 61,321 01/06/22